For Package Inserts, please click on the NDC#. Presentation(s):1g; Reference Listed Drug:Invanz®; Therapeutic Class: Antibacterial, carbapenem type. INVANZ 1 g powder for concentrate for solution for infusion. 2. . This medicinal product contains approximately mEq (approximately mg) of sodium per g dose which should Package Leaflet: information for the user. INVANZ 1 . Product Availability · Contact Us · Make An Inquiry. () Product Summary. Ertapenem Sodium Injection. Therapeutic Class: Carbapenem Antibiotic.
|Published (Last):||20 May 2010|
|PDF File Size:||6.20 Mb|
|ePub File Size:||16.35 Mb|
|Price:||Free* [*Free Regsitration Required]|
The MICs are defined for Staphylococcus sp. Ertapenem is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Anticonvulsive therapy should be continued in patients with a known seizure disorder.
Ertapenem has a short PAE of 1. Infants and Children 3 months to 12 years.
Additionally, increased monitoring of the INR, especially during initiation and upon discontinuation of the antibiotic, may be necessary.
Accumulation does not occur following multiple IM doses in healthy adults. Consider transitioning to an appropriate oral therapy after at least 3 days of parenteral therapy, once clinical improvement has been demonstrated.
No intraoperative redosing and duration of prophylaxis less than 24 hours are suggested by clinical practice guidelines. Consideration should be given to the diagnosis of pseudomembranous colitis in patients presenting with diarrhea following antibacterial administration. Guidelines recommend ertapenem for 4 to 7 days for mild-to-moderate community-acquired infections, including perforated or abscessed appendicitis.
If ertapenem is given within 6 hours of hemodialysis, a supplementary dose of mg is recommended following the hemodialysis session. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. Recipient’s Email Pafkage multiple email address with a comma Please enter valid email address Recipient’s email is required. If the drugs are coadministered and serum valproic acid concentrations cannot be maintained or if seizures occur, alternative antibacterial or anticonvulsant therapy should be considered.
FDA-approved dosage in renal failure for adults: A supplemental dose may or may not be required following dialysis. Carbapenems can inserh serum concentrations of valproic acid to subtherapeutic levels when the two drugs are administered together.
Ertapenem exhibits bactericidal activity due inhibition of cell wall synthesis mediated via binding to penicillin binding proteins PBPs. However, it is theorized that a combination of resistance mechanisms is required for significant carbapenem resistance.
IM use is contraindicated in patients with an amide local anesthetic hypersensitivity. It is ertaapenem that systemic use of antibiotics predisposes patients to development of pseudomembranous colitis.
The IM reconstituted formulation is not for IV use. In animal studies evaluating doses lnsert. It is eliminated via the kidney with a prolonged half-life of roughly 4. Monitor patients for signs and symptoms of bleeding. Major Concomitant use of carbapenems doripenem, ertapenem, imipenem, meropenem and valproic acid is not recommended.
If focal tremor or myoclonic seizures occur, patients should be evaluated neurologically. Patients who have experienced anaphylactic reactions to penicillins or cephalosporins should not receive ertapenem.
Ertapenem Sodium Injection – Par Sterile Products – Products
However, specific intrinsic or acquired beta-lactamases, generally called carbapenemases, can hydrolyze the carbapenems. Ertapenem is stable against hydrolysis ertapebem a variety of beta-lactamases, including penicillinases, cephalosporinases and extended-spectrum beta-lactamases.
It exhibits non-linear pharmacokinetics due to a high level of concentration-dependent plasma protein binding to albumin. Other dosage adjustment guidelines for adults: In the colon, overgrowth of Clostridia may exist when normal flora is altered subsequent to antibacterial administration. Concurrent administration of ertapenem ertapfnem probenecid is not recommended.
Ertapenem for Injection
Surgical intervention is the primary therapeutic intervention. For the treatment of complicated urinary tract infection UTI pyelonephritisincluding cases with nisert bacteremia.
In vitro studies have also shown that it does not inhibit p-glycoprotein-mediated transport of digoxin or vinblastine. Intravenous or Intramuscular dosage.
According to OBRA, use of antibiotics should be limited to confirmed or suspected bacterial infections. Ertapenem is administered via intravenous IV or intramuscular IM routes.
The MICs are defined for Enterobacteriaceae as susceptible at 0. There are no data on the effects of ertapenem on the breast-fed infant or on milk production. Peak plasma concentrations following a 1 g dose are achieved in roughly 2. The toxin produced by Clostridium difficile is a primary cause of pseudomembranous colitis.
Any antibiotic may cause diarrhea, nausea, vomiting, anorexia, and hypersensitivity reactions. Practitioners should be aware that antibiotic-associated colitis has been observed to occur over two months or more following discontinuation of systemic antibiotic therapy; a careful medical history should be taken. No data are available regarding use in pediatric patients with renal impairment. In some instances, this effect is used therapeutically to increase availability of the antimicrobial agent.
It was concluded that the antibiotics ampicillin, ciprofloxacin, clarithromycin, doxycycline, metronidazole, ofloxacin, roxithromycin, temafloxacin, erapenem tetracycline did not alter plasma concentrations of OCs. Immediately transfer the appropriate amount eratpenem the reconstituted vial to diluent.
Prescribing ertapenem in the absence of a proven or strongly suspected bacterial infection or for a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.